Can Fite Biopharma Stock Odds of Future Stock Price Finishing Over 16.79
| CANF Stock | USD 1.61 0.01 0.62% |
Can |
Can Fite Target Price Odds to finish over 16.79
The tendency of Can Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 16.79 or more in 90 days |
| 1.61 | 90 days | 16.79 | close to zero percent |
Based on a normal probability distribution, the odds of Can Fite to move over $ 16.79 or more in 90 days from now is close to zero percent (This Can Fite Biopharma probability density function shows the probability of Can Stock to fall within a particular range of prices over 90 days) . Probability of Can Fite Biopharma price to stay between its current price of $ 1.61 and $ 16.79 at the end of the 90-day period is roughly 96.0 .
Given the investment horizon of 90 days Can Fite has a beta of 0.84 suggesting as returns on the market go up, Can Fite average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Can Fite Biopharma will be expected to be much smaller as well. Additionally Can Fite Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Can Fite Price Density |
| Price |
Predictive Modules for Can Fite
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Can Fite Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Can Fite Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Can Fite is not an exception. The market had few large corrections towards the Can Fite's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Can Fite Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Can Fite within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.54 | |
β | Beta against Dow Jones | 0.84 | |
σ | Overall volatility | 0.31 | |
Ir | Information ratio | -0.12 |
Can Fite Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Can Fite for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Can Fite Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Can Fite Biopharma generated a negative expected return over the last 90 days | |
| Can Fite Biopharma may become a speculative penny stock | |
| Can Fite Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 810 K. | |
| Can Fite Biopharma currently holds about 12.77 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Can Fite Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Bears are Losing Control Over CanFite Biopharma , Heres Why Its a Buy Now |
Can Fite Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Can Stock often depends not only on the future outlook of the current and potential Can Fite's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Can Fite's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.3 M | |
| Cash And Short Term Investments | 8.9 M |
Can Fite Technical Analysis
Can Fite's future price can be derived by breaking down and analyzing its technical indicators over time. Can Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Can Fite Biopharma. In general, you should focus on analyzing Can Stock price patterns and their correlations with different microeconomic environments and drivers.
Can Fite Predictive Forecast Models
Can Fite's time-series forecasting models is one of many Can Fite's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Can Fite's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Can Fite Biopharma
Checking the ongoing alerts about Can Fite for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Can Fite Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Can Fite Biopharma generated a negative expected return over the last 90 days | |
| Can Fite Biopharma may become a speculative penny stock | |
| Can Fite Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 810 K. | |
| Can Fite Biopharma currently holds about 12.77 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Can Fite Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Bears are Losing Control Over CanFite Biopharma , Heres Why Its a Buy Now |
Check out Can Fite Backtesting, Can Fite Valuation, Can Fite Correlation, Can Fite Hype Analysis, Can Fite Volatility, Can Fite History as well as Can Fite Performance. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.